# Gradient-Boosted Decision Trees

Cognitive differences in psychotic disorders have mostly been grouped by diagnosis or drug dose, leaving the medication's own contribution hard to isolate. A cross-sectional study converted prescriptions for 1,067 patients into individualised occupancy profiles across 49 drugs and 32 receptor targets, then used gradient boosting to predict cognition. Shuffling the receptor profiles within diagnosis roughly halved the pharmacological contribution, with negative signal concentrated in a cluster of alpha2-adrenergic, DRD4, DRD5 and several serotonergic receptors, while dopamine transporter SLC6A3 occupancy tracked better cognition.

Cognitive differences in psychotic disorders have mostly been grouped by diagnosis or drug dose, leaving the medication's own contribution hard to isolate. A cross-sectional study converted prescriptions for 1,067 patients into individualised occupancy profiles across 49 drugs and 32 receptor targets, then used gradient boosting to predict cognition. Shuffling the receptor profiles within diagnosis roughly halved the pharmacological contribution, with negative signal concentrated in a cluster of alpha2-adrenergic, DRD4, DRD5 and several serotonergic receptors, while dopamine transporter SLC6A3 occupancy tracked better cognition.